{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:40:15Z","timestamp":1790073615328,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vericiguat was developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. Guidelines recommend long\u2010acting nitrates, such as isosorbide mononitrate, for angina prophylaxis in chronic coronary syndromes (CCS), common comorbidities in HF. This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co\u2010administered vericiguat and isosorbide mononitrate in patients with CCS. In this phase Ib, double\u2010blind, multicenter study, patients were randomized 2:1 to receive vericiguat plus isosorbide mononitrate (<jats:italic>n<\/jats:italic> = 28) or placebo plus isosorbide mononitrate (<jats:italic>n<\/jats:italic> = 13). Isosorbide mononitrate was uptitrated to a stable dose of 60\u00a0mg once daily, followed by co\u2010administration with vericiguat (uptitrated every 2\u00a0weeks from 2.5\u00a0mg to 5\u00a0mg and 10\u00a0mg) or placebo. Thirty\u2010five patients completed treatment (vericiguat, <jats:italic>n<\/jats:italic> = 23; placebo, <jats:italic>n<\/jats:italic> = 12). Mean baseline\u2010 and placebo\u2010adjusted vital signs showed reductions of 1.4\u20135.1\u00a0mmHg (systolic blood pressure) and 0.4\u20132.9\u00a0mmHg (diastolic blood pressure) and increases of 0.0\u20131.8 beats per minute (heart rate) with vericiguat plus isosorbide mononitrate. No consistent vericiguat dose\u2010dependent PD effects were noted. The incidence of adverse events (AEs) was 92.3% and 66.7% in the vericiguat and placebo groups, respectively, and most were mild in intensity. Blood pressure and heart rate changes observed with vericiguat plus isosorbide mononitrate were not considered clinically relevant. This combination was generally well\u2010tolerated. Concomitant use of vericiguat with isosorbide mononitrate is unlikely to cause significant AEs beyond those known for isosorbide mononitrate.<\/jats:p>","DOI":"10.1111\/cts.13238","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T21:43:13Z","timestamp":1647553393000},"page":"1204-1214","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8931-4564","authenticated-orcid":false,"given":"Michael","family":"Boettcher","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Bayer AG  Wuppertal Germany"},{"name":"Graduate Physicist and Physician and Lecturer at the University of Applied Science at the RFH\u2010Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology II Section Clinical Pharmacology Heart Center University of Freiburg  Bad Krozingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Dirk","family":"D\u00fcngen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Donath","sequence":"additional","affiliation":[{"name":"SocraTec R&amp;D GmbH  Erfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Werner","sequence":"additional","affiliation":[{"name":"Heart Center Trier Krankenhaus der Barmherzigen Bruder  Nordallee, Trier Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine University Medical Center  Hamburg Eppendorf, Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Besche","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH &amp; Co. KG  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schulz\u2010Burck","sequence":"additional","affiliation":[{"name":"Bayer AG, Research &amp; Development Pharmaceuticals  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Gerrits","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp a Subsidiary of Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hung","sequence":"additional","affiliation":[{"name":"Clinical Operations Study Medical Experts Bayer SA  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-6726","authenticated-orcid":false,"given":"Corina","family":"Becker","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Bayer AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.028"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.049"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.008"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12005"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2007.08.010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht296"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.02.009"},{"key":"e_1_2_9_12_1","volume-title":"Reactive Oxygen Species. Handb Exp Pharmacol","author":"Sandner P"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.135"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2018-0155"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000536"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928"},{"key":"e_1_2_9_17_1","unstructured":"Food and Drug Administration.VERQUVO prescribing information.2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214377s000lbl.pdf. Accessed February 24 2021."},{"key":"e_1_2_9_18_1","unstructured":"Bayer plc.Verquvo 10 mg film\u2010coated tablets SmPC.2021.https:\/\/www.medicines.org.uk\/emc\/product\/12775\/smpc#gref. Accessed August 27 2021."},{"key":"e_1_2_9_19_1","first-page":"A19938","article-title":"Abstract 19938: VEriciguat NItroglycerin Clinical IntEraction (VENICE): a phase 1, multicenter, randomized, placebo\u2010controlled, double\u2010blind group\u2010comparison study in patients with stable coronary artery disease to evaluate tolerability and blood pressure effects of nitroglycerin after pre\u2010treatment with multiple oral doses of vericiguat","volume":"136","author":"Duengen H\u2010D","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"e_1_2_9_20_1","first-page":"295","article-title":"Pharmacodynamic interaction study of a long\u2010acting nitrate co\u2010administered with vericiguat in patients with stable coronary artery disease","volume":"21","author":"Boettcher M","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03023-7"},{"key":"e_1_2_9_22_1","volume-title":"Imdur tablets 60 mg: Summary of product characteristics","author":"TopRidge Pharma Ltd","year":"2018"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15734"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw593"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15922"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.013"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:52:34Z","timestamp":1692849154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/cts.13238"],"URL":"https:\/\/doi.org\/10.1111\/cts.13238","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"2021-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}